The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,761.00
Bid: 1,757.50
Ask: 1,758.00
Change: 27.50 (1.59%)
Spread: 0.50 (0.028%)
Open: 1,736.00
High: 1,767.00
Low: 1,736.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: Plus500 Up On Share Buyback, New Customers

Tue, 13th Aug 2019 10:09

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Tuesday.----------FTSE 100 - WINNERS----------TUI, up 3.5%. The Anglo-German travel company reported revenue growth on strong performances by its experiences businesses in the third quarter. For the three months ended June, revenue rose 3.7% to EUR4.75 billion from EUR4.58 billion the year before. Revenue was supported by strong performances by the Destination Experiences, Holiday Experiences, and Cruises divisions. This was offset by weakness in the Western Region, Northern Region, and All Other Segments units. However, underlying earnings before interest, taxes & amortisation narrowed 46% to EUR100.9 million from EUR186.8 million a year prior. Profit performance was hurt by the Markets & Airlines unit sinking to a EUR103.9 million underlying Ebita loss from a EUR37.2 million profit the year prior. TUI reiterated its full-year guidance for underlying Ebita to fall by up to 26% from last year. "TUI had the kitchen-sink experience earlier in the year with two profit warnings, so the fact that there are no further shocks has resulted in a warm share price reaction to these numbers," said Interactive Investor's Richard Hunter. ----------GlaxoSmithKline, up 0.5%. JPMorgan restarted coverage on the drugmaker with a Neutral rating.----------FTSE 100 - LOSERS----------Rolls-Royce Holdings, down 2.7%. Moody's Investors Service downgraded the credit rating for the jet engine maker citing weak cash flow and high leverage levels. The credit ratings agency downgraded the long-term debt rating for the FTSE 100-listed firm to Baa1 from A3 previously. The outlook was boosted to Stable from Negative. Moody's downgraded the rating for Rolls-Royce amid adjusted leverage levels sitting at 5.3 times earnings, with the credit analyst not expecting this to fall below 4.0 times over the next year to year-and-a-half. The high cost of rectifying issues with the cracking blades of the Trent 1000 aircraft engines, as well as "limited" free cash flow also worried Moody's. ----------Croda International, down 2.2%. Goldman Sachs cut the speciality chemicals company to Sell from Neutral. ----------FTSE 250 - WINNERS----------Plus500, up 19%. The spread betting and contract-for-difference said it has "performed well", despite reporting a steep drop in both revenue and profitability and also slashing its dividend. Plus500's revenue for the six months to June fell 68% year-on-year to USD148.0 million, with pretax profit slumping 82% to USD63.9 million. Plus500's net profit fell 80% to USD51.6 million, with earnings before interest, taxes, depreciation, and amortisation down 81% to USD65.6 million. Plus500 will be returning USD0.2734 per share to shareholders for the period, an 80% reduction from the USD1.3786 paid out a year before. However, the firm has also announced a share buyback worth USD50.0 million. The company said the performance was in line with expectations, with the second quarter improving on the first after financial markets volatility increased. Second quarter new customer numbers were 23% ahead of the first quarter, with active customer numbers rising 11%. ----------FTSE 250 - LOSERS----------Aston Martin Lagonda, down 4.0%. Credit Suisse downgraded the Valkyrie hypercar maker to Neutral from Outperform. ----------OTHER MAIN MARKET AND AIM - WINNERS----------Oilex, up 60%. The oil and gas company announced its request for a halt in the trading of its shares on the Australian Stock Exchange was granted with immediate effect. Oilex said its suspension on the ASX is in relation to a proposed acquisition, and will be in place until Thursday, when it makes an announcement relating to the acquisition. Trading in Oilex's shares on London's AIM however will continue during the period. On Wednesday last week, Oilex agreed to acquire Holloman Energy Corp's 48% interest in the PEL 112 and PEL 444 licences within the Cooper-Eromanga basins, onshore Australia for AUD145,500 in cash and shares.----------OTHER MAIN MARKET AND AIM - LOSERS----------John Menzies, down 4.5%. The aviation services firm blamed the grounding of Boeing Co's 737 MAX and weak cargo volumes for an interim loss. John Menzies's pretax loss for the six months to June was GBP4.4 million, after a GBP8.3 million profit the year before. On an underlying basis, pretax profit was down 47% to GBP8.2 million. The company did manage to increase revenue, by 3.6% to GBP649.9 million and has kept the interim payout flat at 6.0 pence a share. John Menzies said the aviation sector has seen a decline in airline flight schedules and reduced cargo volumes, while the company has also been hurt by contract losses in the Dominican Republic and Panama. The firm is now looking to deliver over GBP10 million of cost savings, most of which will be realised in 2020, with "decisive" action now taken to "right size" the business. ----------

More News
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.